Johnson & Johnson logo

Johnson & Johnson (JNJ)

Market Closed
16 Oct, 08:00 PM
NYSE NYSE
$
255. 56
+2.28
+0.9002%
$
615.87B Market Cap
29.06 P/E Ratio
0.69% Div Yield
6.55M Volume
9.91 Eps
$ 253.28
Previous Close
Add Transaction
Day Range
254 257.55
Year Range
184.66 281.07
Want to track JNJ and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Johnson & Johnson Latest Talc Resolution Rejected. The Stock Is Falling.

Johnson & Johnson Latest Talc Resolution Rejected. The Stock Is Falling.

A bankruptcy judge in Texas rejected a proposal that would have ended most lawsuits saying the products cause ovarian cancer.

Barrons | 1 year ago
J&J shares fall after judge rejects $10 billion talc settlement

J&J shares fall after judge rejects $10 billion talc settlement

Johnson & Johnson shares fell more than 3% on Tuesday after a U.S. bankruptcy judge rejected its $10 billion proposal to end tens of thousands of lawsuits alleging that its baby powder and other talc products cause ovarian cancer.

Reuters | 1 year ago
US judge rejects J&J's $10 billion baby powder settlement

US judge rejects J&J's $10 billion baby powder settlement

A U.S. bankruptcy judge on Monday rejected Johnson & Johnson's $10 billion proposal to end lawsuits alleging that its baby powder and other talc products cause ovarian cancer, marking the third time the company's bankruptcy strategy has failed in court.

Reuters | 1 year ago
US judge rejects J&J's $10 billion baby powder settlement

US judge rejects J&J's $10 billion baby powder settlement

A U.S. bankruptcy judge on Monday rejected Johnson & Johnson's $10 billion proposal to end lawsuits alleging that its baby powder and other talc products cause ovarian cancer, marking the third time the company's bankruptcy strategy has failed in court.

Reuters | 1 year ago
Why Johnson & Johnson (JNJ), United Health (UNH) And Procter & Gamble (PG) Are Holding the S&P 500 From Dropping More

Why Johnson & Johnson (JNJ), United Health (UNH) And Procter & Gamble (PG) Are Holding the S&P 500 From Dropping More

As President Trump's April 2nd “Liberation Day” approaches, the stock market has been selling off due to uncertainties on the impact of the tariff policy implementation intended to even out the presently skewed international playing field.

247wallst | 1 year ago
Are You Looking for a High-Growth Dividend Stock?

Are You Looking for a High-Growth Dividend Stock?

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?

Zacks | 1 year ago
JNJ's Rybrevant-Lazcluze Combo Outshines AZN's Tagrisso in Lung Cancer

JNJ's Rybrevant-Lazcluze Combo Outshines AZN's Tagrisso in Lung Cancer

Study investigators expect that J&J's combo drug can extend overall survival by at least a year over the current standard of care in certain NSCLC patients.

Zacks | 1 year ago
Procter & Gamble, Johnson & Johnson Among 10 Companies To Announce Dividend Increases In First Half Of April

Procter & Gamble, Johnson & Johnson Among 10 Companies To Announce Dividend Increases In First Half Of April

This is my latest article where I provide predictions of upcoming dividend increases from companies with long-term dividend growth histories. A slow March brought mid-single digit percentage dividend boosts from consumer goods company Colgate-Palmolive and defense contractor General Dynamics. Widely-held Johnson & Johnson, Procter & Gamble, and Costco will announce increases in the first half of April.

Seekingalpha | 1 year ago
Johnson & Johnson Needs Time To Consolidate (Technical Analysis And Downgrade)

Johnson & Johnson Needs Time To Consolidate (Technical Analysis And Downgrade)

Two recent catalysts, one technical and one fundamental, have promoted me to adjust my rating on JNJ to a HOLD from my earlier buy rating. Technical trading patterns signal that JNJ is entering a consolidation phase with no clear directional momentum in the near term. In the meantime, JNJ's valuation ratios have expanded, narrowing the discount compared to historical averages and shifting its return/risk profile.

Seekingalpha | 1 year ago
Johnson & Johnson unit ordered to pay $1.64 billion in HIV drug marketing case

Johnson & Johnson unit ordered to pay $1.64 billion in HIV drug marketing case

A federal judge ordered a Johnson & Johnson unit on Friday to pay the U.S. government $1.64 billion after a jury found it liable in a whistleblower lawsuit for illegally promoting the HIV drugs Prezista and Intelence.

Reuters | 1 year ago
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know

Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.

Zacks | 1 year ago
2 Recession-Proof Dividend Stocks to Buy and Hold

2 Recession-Proof Dividend Stocks to Buy and Hold

Fears of a looming recession seem to be rising, partly fueled by President Donald Trump's macroeconomic policies. While it's impossible to predict whether an economic downturn is indeed coming, it's not a bad idea for investors to purchase shares of companies that are likely to perform relatively well in case it does happen.

Fool | 1 year ago
Loading...
Load More